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Improving survival outcomes for patients presenting with mediastinal 
lymph nodes, Stage IIIa, N-2, motivates thoracic surgeons, medical 
oncologists and radiation oncologists alike. All desire the best treat-
ment for the most patients, but we continue to debate what current 
tactics are most likely to result model that we can readily adopt. With 
an eye to the future, most hope that a gene array or molecular identiﬁer 
will forecast which patients have tumors with genetic packages that 
are amenable to curative therapy. Alas, we are not to that point today, 
and the 30% of NSCLC patients with heterogeneous stage IIIa disease 
variously are treated with the best of intentions based on a rather 
weak foundation of clinical trials. All stage IIIa is not the same, and 
a one-size ﬁts all, bi- or tri- modal therapy is likely to be error-prone 
and unsatisfactory to us all. What is abundantly clear is that no single 
modality alone is appropriate, and the wish for surgery to be the most 
successful tactic leads us into the temptation to use it more widely than 
appropriate for the extant data. The same can be said for radiotherapy 
alone, which is clearly inferior to radiotherapy plus chemotherapy in 
patients that can tolerate chemotherapy. Unlike the stringent winnow-
ing process selecting patients for surgery, radiotherapy discriminates 
less and can more easily be applied to the entire population presenting 
with lung cancer. Poor heart and lung functions are not the same barrier 
for radiotherapy as these are for surgery. The presence of N-2 nodes 
indicates that the deranged tumor cell-line has metastatic potential 
beyond the thorax, more likely than not. Thus, it is quite clear that the 
use of chemotherapy in N-2 patients is desirable on theoretic grounds 
(they metastasize) and clinical data (survival) is better, but we must 
remember that the studies done supporting that always mandate that 
the patients have good performance status and can withstand systemic 
therapy. Cisplatin is the most universally accepted drug, but pairing it 
with another agent has not resulted in a combination that everyone is 
willing to use. Europeans have recognized this and allowed investigator 
physicians to choose what other drug to add to cisplatin. 
The landmark CALGB study initiated in 1984 established that this 
platinum-based chemotherapy added to radiotherapy was better than 
radiotherapy alone (Dillman). Over the ensuing two decades, there 
have been nationalistic tendencies to use certain chemotherapy pairs 
with cisplatin, or even carboplatinum, but no pair of drugs emerges as 
superior, and three drugs seems to increase toxicity without adding a 
survival gain. The international standard of care for stage IIIa patients 
remains chemoradiotherapy, but the drugs, the timing of the two modal-
ities (concurrent or sequential) and the penetrating question of whether 
a select subset might beneﬁt from more remains unanswered. Under-
powered phase III and highly publicized phase II studies have tried to 
establish chemotherapy for two or three cycles followed by surgery. 
Even for N-0 patients and for N-2 patients, the complete response is in 
the single digits, or if reported higher, the conﬁdence interval includes 
less than 10% (Pisters et al). Many have clamored for the newer che-
motherapy agents introduced in the 1990’s, particularly carboplatinum 
paclitaxel in the US, and while these are used, none of these have actu-
ally added substantially to the cisplatin plus a “V” drug combination.
Tri-modal therapy began with the SWOG trial 8805 (Albain et al). This 
trial’s 120 plus patients provided the data that formed the basis and the 
hypothesis for the US Intergroup 0139 trial. The backbone of both trials 
is cisplatin etoposide and concurrent radiotherapy, 45 Gy preoperative-
ly, or 61 Gy deﬁnitively in the non-surgical arm of the Intergroup trial. 
Those that had induction chemoradiotherapy had a 10 - 30% chance of 
complete pathologic response in N-2 nodes, and these patients had long 
term prospect of survival, whereas those with residual disease in nodes 
almost universally failed. Moreover, supplementary post operative 
therapy (post operative boost radiotherapy or adjuvant chemotherapy) 
only increased morbidity and did nothing to salvage these less than 
complete nodal responders.
The major trials addressing the addition of surgery remain inconclu-
sive. The largest and purest is the US Intergroup 0139, where patients 
were randomized to chemoradiotherapy to full radiotherapy dose of 
61 Gy or truncating the dose to 45 Gy when used pre-operatively, both 
concurrent with cisplatin etoposide chemotherapy (Albain 2). Despite 
a signiﬁcant beneﬁt in disease free survival, there was no signiﬁcant 
beneﬁt in overall survival. Subset analyses show a hazard to pneumo-
nectomy, particularly right sided, and a potential for beneﬁt in patients 
requiring lobectomies. The negative impact of right pneumonectomies 
on overall survival has been pinned on the tri-modal therapy implicat-
ing the radiotherapy. Martin et al ﬁrst called attention to the identical 
25% mortality from a Memorial series that used chemotherapy alone, 
and indeed many sources note increased mortality with the pneumo-
nectomy by itself without any adjuvant therapy. Andre forecast from 
over 700 French patients with N-2 NSCLC that four factors were key: 
single station, single lymph nodes, clinically obvious nodes by imaging 
did worse than incidental nodes, and using neoadjuvant chemotherapy. 
VanMeerbeck and the EORTC recently reported a trial using 2 to three 
induction cycles of chemotherapy based on a platinum plus one other 
modern drug. Nearly half of the 579 patients registered were random-
ized to resection or radiotherapy, but 47% of patients did not proceed 
after induction therapy for a variety of reasons. Despite eliminating 
some of the most unfavorable cases during the induction treatment, 
there was no difference in median or ﬁve year survival. The US Inter-
group has not been closed a minimum of 6 years, but at last report, sur-
gery achieved 27% and chemoradiotherapy 20% 5 year survival (NS). 
The EORTC trial reported 16% versus 17% 5 year survival (NS) for 
patients randomized to surgery and radiotherapy respectively. Undoubt-
edly there were differences in selection and other factors between these 
studies, but the EORTC study had the more modern chemotherapy, and 
the US Intergroup study was less successful in administering the post 
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operative chemotherapy in patients subjected to surgery, and the radio-
therapy treatment plan compliance was faulty in 20% of cases.
Some believe that chemotherapy can achieve better results when 
used alone, and that radiotherapy adds nothing but morbidity. While 
this ultimately may prove correct, the current data suggest that nodal 
response is less, and that morbidity seems to be more associated with 
pneumonectomy than radiotherapy use. Those advocating radiotherapy 
underscore the enhanced complete response rate, and the possibil-
ity of eliminating clones of chemotherapy resistant cells. The US 
has mounted a trial comparing induction docetaxel platinum alone to 
docetaxel platinum plus radiotherapy prior to resection. It is accruing 
very slowly. Intrinsic factors such as number of nodes, number of nodal 
levels positive for cancer, and bulk - all hard to deﬁne pre-operative 
- may be telling, and how these factors are allocated may inﬂuence the 
results of randomized trials more than the treatment itself.
The standard bi-modal management is chemoradiotherapy. This should 
be the control arm of any trial testing the value of surgery, which seems 
very attractive, but remains of unproven value in stage IIIa disease.
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The worldwide epidemic of lung cancer is a major public health 
concern, not only because of the enormous loss of life and the great 
morbidity it causes, but also because of the large economic burden it 
places on health care systems and society in general. Based largely on 
1990 data sources, the economic burden of cancer in general has been 
estimated in the United States at $US 27.5 billion for direct health care 
costs including hospitalized care costs of $17.9 billion. Indirect costs 
have been estimated at a further $58.7 billion. As a percentage of the 
total health care expenditures in the United States, cancer constitutes 
about 4.7% of all costs.
Based on expenditure data from the 1996 Surveillance, Epidemiology 
and End Results (SEER) database, Brown et al. estimated the direct 
medical care costs to be $4.7 billion for lung cancer (1). A cost per case 
study from California in 1997 estimated the long-term costs of care 
for lung cancer to be $33,000 compared with $35,000 for breast and 
$42,000 for colon (2).
The total cost burden of lung cancer will be high in industrial countries 
where the high incidence of lung cancer and adequate resources enable 
state-of-the-art care to be given. This economic burden may exceed the 
capacity of developing countries to provide appropriate evidence-based 
care. Even wealthy nations are experiencing increasing ﬁscal constraint 
which is forcing governments and health care administrators to criti-
cally examine the value of health care interventions and the efﬁciency 
of health care delivery systems.
Health economic data may be presented in many forms - as the cost to 
treat an individual (cost per case), as the economic impact to the funder 
(government in a publicly funded system; an insurer in a private cover-
age system) of the total number of treated cases over a deﬁned period, 
or as the costs in relation to the consequences in comparison to alterna-
tive interventions. The latter is increasingly expected by governments 
prior to approval as it provides an estimate of the value of the interven-
tion against the money expended. 
A cost-effectiveness analysis is the most common of these analyses and 
provides information on the incremental cost of the intervention com-
pared to the standard therapy over the incremental beneﬁt measured 
in life years gained. The incremental cost per case (ICER) can then be 
used by decision makers to determine if a new therapy represents good 
value for money or is cost-effective. A value less than $50,000 per life 
year gained (LYG) is generally accepted as “cost-effective” but there 
is little to recommend this speciﬁc number. A range is more acceptable 
and may be of the magnitude of $20,000-100,000/LYG. The weakness 
of the cost effectiveness analysis is that it does not take account of the 
morbidity of the disease state and its treatment. A quality adjusted life 
year (QALY) incorporates morbidity into a single multi-dimensional 
measure (i.e. the quantity of life gained by treatment is weighted by 
the quality of that life). The quality of life is approximated by a util-
ity which is a measure of preference for a given health state rated on 
a scale where 0 equals death and 1 equals perfect health. “Standard 
gamble” exercises, time trade off and direct rating on a visual analogue 
scale can be used, as well as speciﬁc instruments such as the Health 
Utilities Index and Euro QoL.
Economic evaluations are relatively speciﬁc to the health care system 
they are performed in and cannot readily be used for decision-making 
in another health care system with a different delivery system, patterns 
of practice and cost structure. In interpreting the results of an economic 
analysis, it is important to be aware of issues such as transparency, the 
use of discounting and sensitivity analysis and the methodologies for 
assessing effectiveness. The interested reader is directed to guidelines 
for reporting economic studies (3) and strategies to critically appraise 
economic analyses (4,5).
Early studies of Canadian lung cancer costs revealed some surprises 
and also helped to guide efforts to use resources more effectively. Stud-
ies from the National Cancer Institute of Canada (6,7) demonstrated 
that the use of chemotherapy in advanced NSCLC could actually be 
a dominant strategy, (i.e. it prolonged survival while reducing costs), 
as it led to the use of fewer radiation and late stage hospital resources. 
